BeiGene Opens Biologics Manufacturing and Clinical R&D Facility in New Jersey
BeiGene has committed $800 million in a new biologics manufacturing plant in Hopewell, New Jersey, which also includes clinical research and development capabilities
BeiGene, an oncology business, announced on July 23, 2024 that it has established a new biologics production facility at the Princeton West Innovation Campus in Hopewell, New Jersey. The facility is the company's flagship location in the United States, and it also features a clinical R&D center. The corporation invested $800 million in the location to increase its integrated manufacturing and R&D footprint in the United States.
BeiGene has around 30 compounds in clinical or commercial development. The new 42-acre facility allows the company to increase production of these therapeutic candidates both now and in the future to fulfill cancer patient demand. The Hopewell site consists of about 400,000 ft2 of space dedicated to commercial-stage biologic manufacturing capacity, with more space to expand over time as BeiGene's.
The facility enhances BeiGene's late-stage research and clinical development capabilities. The company's oncology pipeline targets 80% of worldwide tumors with modalities such as targeted degraders, antibody drug conjugates, monoclonal antibodies, and conventional small molecules. The new facility allows the company to produce at scale, lowering costs and increasing supply chain resilience. According to a news release, the company's goals are to avoid global interruptions, protect capacity, and quickly respond to the most inventive modalities.
"BeiGene has experienced unprecedented global growth, and the addition of our facility at the Princeton West Innovation Campus adds manufacturing and clinical development capabilities that will further strengthen our differentiated strategy, which leverages speed, efficiency, and technology to advance quality medicines faster for patients," stated John Oyler, co-founder, CEO, and chairman of BeiGene, according to a release. "We are happy to be a part of New Jersey's biopharmaceutical ecosystem, which is strong in R&D and manufacturing talent. We are excited to strengthen our partnerships with key regional research institutions as we progress our robust pipeline of next-generation hematological and solid tumor treatments and continue to emerge as a leading global cancer innovation."
By the end of 2025, the company aims to have created hundreds of skilled high-tech employment on-site. BeiGene initially announced plans to build on the Hopewell site in November 2021.
"I am thrilled by BeiGene's contribution to our state's thriving biopharmaceutical sector," Governor Phil Murphy said in a statement. "The opening of BeiGene's flagship campus demonstrates our commitment to fostering innovation and creating high-tech jobs in the Garden State." We are looking forward to BeiGene's good impact on our economy and the advances they will bring to cancer therapy. This enormous investment underlines New Jersey's global leadership in pharmaceutical production, research, and development. We are happy to support BeiGene's aim of developing inexpensive and accessible cancer treatments for patients globally."
As part of BeiGene's environmental initiatives, the corporation has invested in sustainability measures both within the buildings and around the 42-acre site. These solutions include a heating and cooling system that uses recycled wastewater from the onsite wastewater treatment facility for cooling towers, as well as solar-ready capabilities.
Source: BeiGene
